Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion, AstraZeneca to buy LogicBio Therapeutics
The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic
The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic
The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution
The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It
This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human
As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies. Genentech,
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are
The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),
Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene
Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization